Lumizyme (alglucosidase alfa) — Medical Benefit Medication Utilization Policy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical benefit coverage criteria, authorization, quantity limits, and coding for Lumizyme (alglucosidase alfa) for treatment of Pompe disease for Community-Care members.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.